

# Steven V Edelman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2759134/publications.pdf>

Version: 2024-02-01

47  
papers

1,679  
citations

394421

19  
h-index

289244

40  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2185  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	2.2	69
2	Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. <i>Primary Care Diabetes</i> , 2021, 15, 199-207.	1.8	13
3	Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107812.	2.3	3
4	Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index $\geq 27 \text{ kg/m}^2$ . <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 854-860.	4.4	14
5	Practical Strategies to Help Reduce Added Sugars Consumption to Support Glycemic and Weight Management Goals. <i>Clinical Diabetes</i> , 2021, 39, 45-56.	2.2	9
6	Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real-world study of more than 30,000 patients in a US electronic health record database. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 622-630.	4.4	20
7	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 845-854.	11.4	46
8	A Tribute to Robert Roy Henry "The Classic Academic Triple Threat" Accomplished Researcher, Inspiring Teacher, and Compassionate Clinician. <i>Diabetes Care</i> , 2020, 43, 522-525.	8.6	0
9	Patients With Type 2 Diabetes Are Willing to Do More to Overcome Therapeutic Inertia: Results From a Double-Blind Survey. <i>Clinical Diabetes</i> , 2020, 38, 222-229.	2.2	5
10	Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes: New findings from the global IntroDia® study. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 89-97.	2.8	10
11	Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 62-77.	4.4	31
12	Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1906-1913.	4.4	9
13	Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients. <i>Clinical Diabetes</i> , 2019, 37, 386-390.	2.2	0
14	Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study. <i>Diabetes Care</i> , 2019, 42, 2220-2227.	8.6	93
15	Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 179-188.	2.8	2
16	Response to Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. <i>Diabetes Care</i> 2017;40:1425-1432. <i>Diabetes Care</i> , 2018, 41, e18-e18.	8.6	0
17	Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2018, 41, 2265-2274.	8.6	120
18	Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 448-451.	4.4	11

#	ARTICLE	IF	CITATIONS
19	Administration of Biosimilar Insulin Analogs: Role of Devices. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 79-84.	4.4	9
20	Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes. <i>American Journal of Medicine</i> , 2017, 130, 614.	1.5	0
21	Physicianâ€“patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDiaÂ® study. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 265-274.	2.8	35
22	Investigating Hypoglycemic Confidence in Type 1 and Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 131-136.	4.4	68
23	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)Â©. <i>Patient</i> , 2017, 10, 321-334.	2.7	9
24	Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. <i>Diabetes Care</i> , 2017, 40, 1425-1432.	8.6	213
25	Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1469-1478.	8.6	112
26	Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. <i>Diabetes Therapy</i> , 2017, 8, 863-873.	2.5	170
27	Improvement of Insulin Injection Technique. <i>The Diabetes Educator</i> , 2016, 42, 379-394.	2.5	60
28	Differences in Use of Glucose Rate of Change (ROC) Arrows to Adjust Insulin Therapy Among Individuals With Type 1 and Type 2 Diabetes Who Use Continuous Glucose Monitoring (CGM). <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1087-1093.	2.2	19
29	The past, present, and future of basal insulins. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 478-496.	4.0	63
30	Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of Life. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 657-663.	4.4	52
31	Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 773-779.	4.4	28
32	Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. <i>Diabetes Care</i> , 2015, 38, 412-419.	8.6	191
33	The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 Diabetes. <i>The Diabetes Educator</i> , 2014, 40, 269-279.	2.5	28
34	Comment on Little et al. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 Ã— 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPASS). <i>Diabetes Care</i> 2014;37:2114â€“2122. <i>Diabetes Care</i> , 2014, 37, e270-e271.	8.6	4
35	Effect of Early Weight Loss on Type 2 Diabetes Mellitus after 2 Years of Gastric Banding. <i>Postgraduate Medicine</i> , 2012, 124, 73-81.	2.0	3
36	Are Patientsâ€™ Initial Experiences at the Diagnosis of Type 2 Diabetes Associated With Attitudes and Self-management Over Time?. <i>The Diabetes Educator</i> , 2010, 36, 828-834.	2.5	22

#	ARTICLE	IF	CITATIONS
37	Continuous Glucose Monitoring Health Outcomes. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-68-S-74.	4.4	16
38	Optimizing Diabetes Treatment Using an Amylin Analogue. <i>The Diabetes Educator</i> , 2008, 34, 4S-10S.	2.5	11
39	Through the Looking Glass. <i>The Diabetes Educator</i> , 2007, 33, 32S-46S.	2.5	3
40	Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 9-18.	2.4	3
41	A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. <i>Osteopathic Medicine and Primary Care</i> , 2007, 1, 9.	0.5	15
42	Does a patient-administered titration algorithm of insulin glargine improve glycemic control?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 78-79.	2.8	0
43	Incretins: What Does the Future Hold?. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 809-812.	4.4	2
44	Strategies for Insulin Therapy in Type 2 Diabetes. <i>Southern Medical Journal</i> , 2005, 98, 363-371.	0.7	18
45	Aiming for, believing in, and achieving a target A1c of less than 7. <i>Journal of the American Pharmacists Association</i> , 2003, 43, 121-2.	0.5	1
46	The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 6, S29-37.	1.4	3
47	Unresolved Challenges with Insulin Therapy in Type 1 and Type 2 Diabetes: Potential Benefit of Replacing Amylin, a Second $\beta$ -Cell Hormone. <i>Diabetes Technology and Therapeutics</i> , 2002, 4, 175-189.	4.4	66